Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma

Abstract Background. Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types. Methods....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 2007-06, Vol.105 (3), p.625-629
Hauptverfasser: Shvartsman, Hyun S, Sun, Charlotte C, Bodurka, Diane C, Mahajan, Vrinda, Crispens, Marta, Lu, Karen H, Deavers, Michael T, Malpica, Anais, Silva, Elvio G, Gershenson, David M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 629
container_issue 3
container_start_page 625
container_title Gynecologic oncology
container_volume 105
creator Shvartsman, Hyun S
Sun, Charlotte C
Bodurka, Diane C
Mahajan, Vrinda
Crispens, Marta
Lu, Karen H
Deavers, Michael T
Malpica, Anais
Silva, Elvio G
Gershenson, David M
description Abstract Background. Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types. Methods. All patients with stages II–IV LGSC (group 1) or with STLMP that recurred as LGSC (group 2) seen at our institution from 1973 to 2003 were identified, and demographic data were obtained. For group 1, progression-free and overall survival times were calculated from the date of primary diagnosis to the date of disease progression/recurrence or the date of last contact/death, respectively. For group 2, progression-free and overall survival times were calculated from the date of first relapse as a LGSC to the date of progression or the date of last contact/death, respectively. The method of Kaplan and Meier was used to estimate survival, and the log-rank test was used to compare differences between survival curves. Results. We identified 112 patients in group 1 and 41 in group 2. There were no statistically significant differences between the two groups in median age (42.7 vs. 45.4 years [at relapse]; P = 0.37), progression-free survival time (19.5 vs. 25 months; P = 0.92), or overall survival time (81.8 vs. 82.8 months; P = 0.84). Conclusions. The age at diagnosis, progression-free survival time, and overall survival time associated with newly diagnosed stages II–IV LGSC of the ovary are similar to those of STLMP that recur as LGSC, providing further evidence of an association between these two tumor types.
doi_str_mv 10.1016/j.ygyno.2007.01.030
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70531906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0090825807000558</els_id><sourcerecordid>70531906</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-d48f413d7d99a8fa611622a983eedb94af52fac4b4ce2f7fdfc0b6bc9e8213383</originalsourceid><addsrcrecordid>eNqFUsuu0zAQjRCIWy58ARLyil3C2HkvQEIVj0pXYsFjazn2pHVJ7GI7rbLjH_g1voAvwbntFRILWFn2ecx4ziTJUwoZBVq92GfzdjY2YwB1BjSDHO4lKwptmVZN2d5PVgAtpA0rm6vkkfd7gEih7GFyReucAS2rVfJzbceDcNpbQ2xPwg6JHLTRUgykw504ausWwOBpmInSYmusR0V8EFv0ZLP59f3H5gsZ7CndOqGQeHR28kQKJ7Wxo7hztUfhZnLSYRevIizPF-qCaGFImEbr_AJENzKKQW-NMIEcbEATdGzoVuhQTo4I_4-aj5MHvRg8Prmc18nnt28-rd-nNx_ebdavb1JZUBZSVTR9QXNVq7YVTS8qSivGRNvkiKprC9GXrBey6AqJrK971Uvoqk622DCa501-nTw_-x6c_TahD3zUXuIwCIOxIV5DmdMWqkjMz0TprPcOe35weowD4RT4Eibf89sw-RImB8pjUlH17GI_dSOqP5pLepHw8kzA-MmjRse91GgkKh2nFLiy-j8FXv2lv8v-K87o93ZyJs6PU-4ZB_5x2adlnaCOq1SWTf4bDQDNrA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70531906</pqid></control><display><type>article</type><title>Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Shvartsman, Hyun S ; Sun, Charlotte C ; Bodurka, Diane C ; Mahajan, Vrinda ; Crispens, Marta ; Lu, Karen H ; Deavers, Michael T ; Malpica, Anais ; Silva, Elvio G ; Gershenson, David M</creator><creatorcontrib>Shvartsman, Hyun S ; Sun, Charlotte C ; Bodurka, Diane C ; Mahajan, Vrinda ; Crispens, Marta ; Lu, Karen H ; Deavers, Michael T ; Malpica, Anais ; Silva, Elvio G ; Gershenson, David M</creatorcontrib><description>Abstract Background. Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types. Methods. All patients with stages II–IV LGSC (group 1) or with STLMP that recurred as LGSC (group 2) seen at our institution from 1973 to 2003 were identified, and demographic data were obtained. For group 1, progression-free and overall survival times were calculated from the date of primary diagnosis to the date of disease progression/recurrence or the date of last contact/death, respectively. For group 2, progression-free and overall survival times were calculated from the date of first relapse as a LGSC to the date of progression or the date of last contact/death, respectively. The method of Kaplan and Meier was used to estimate survival, and the log-rank test was used to compare differences between survival curves. Results. We identified 112 patients in group 1 and 41 in group 2. There were no statistically significant differences between the two groups in median age (42.7 vs. 45.4 years [at relapse]; P = 0.37), progression-free survival time (19.5 vs. 25 months; P = 0.92), or overall survival time (81.8 vs. 82.8 months; P = 0.84). Conclusions. The age at diagnosis, progression-free survival time, and overall survival time associated with newly diagnosed stages II–IV LGSC of the ovary are similar to those of STLMP that recur as LGSC, providing further evidence of an association between these two tumor types.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2007.01.030</identifier><identifier>PMID: 17320156</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Cystadenocarcinoma, Serous - drug therapy ; Cystadenocarcinoma, Serous - pathology ; Cystadenocarcinoma, Serous - radiotherapy ; Cystadenocarcinoma, Serous - surgery ; Disease-Free Survival ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Low-grade serous carcinoma ; Middle Aged ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Obstetrics and Gynecology ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - radiotherapy ; Ovarian Neoplasms - surgery ; Serous ovarian tumor of low malignant potential ; Survival Rate</subject><ispartof>Gynecologic oncology, 2007-06, Vol.105 (3), p.625-629</ispartof><rights>2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-d48f413d7d99a8fa611622a983eedb94af52fac4b4ce2f7fdfc0b6bc9e8213383</citedby><cites>FETCH-LOGICAL-c412t-d48f413d7d99a8fa611622a983eedb94af52fac4b4ce2f7fdfc0b6bc9e8213383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ygyno.2007.01.030$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17320156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shvartsman, Hyun S</creatorcontrib><creatorcontrib>Sun, Charlotte C</creatorcontrib><creatorcontrib>Bodurka, Diane C</creatorcontrib><creatorcontrib>Mahajan, Vrinda</creatorcontrib><creatorcontrib>Crispens, Marta</creatorcontrib><creatorcontrib>Lu, Karen H</creatorcontrib><creatorcontrib>Deavers, Michael T</creatorcontrib><creatorcontrib>Malpica, Anais</creatorcontrib><creatorcontrib>Silva, Elvio G</creatorcontrib><creatorcontrib>Gershenson, David M</creatorcontrib><title>Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Abstract Background. Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types. Methods. All patients with stages II–IV LGSC (group 1) or with STLMP that recurred as LGSC (group 2) seen at our institution from 1973 to 2003 were identified, and demographic data were obtained. For group 1, progression-free and overall survival times were calculated from the date of primary diagnosis to the date of disease progression/recurrence or the date of last contact/death, respectively. For group 2, progression-free and overall survival times were calculated from the date of first relapse as a LGSC to the date of progression or the date of last contact/death, respectively. The method of Kaplan and Meier was used to estimate survival, and the log-rank test was used to compare differences between survival curves. Results. We identified 112 patients in group 1 and 41 in group 2. There were no statistically significant differences between the two groups in median age (42.7 vs. 45.4 years [at relapse]; P = 0.37), progression-free survival time (19.5 vs. 25 months; P = 0.92), or overall survival time (81.8 vs. 82.8 months; P = 0.84). Conclusions. The age at diagnosis, progression-free survival time, and overall survival time associated with newly diagnosed stages II–IV LGSC of the ovary are similar to those of STLMP that recur as LGSC, providing further evidence of an association between these two tumor types.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Cystadenocarcinoma, Serous - drug therapy</subject><subject>Cystadenocarcinoma, Serous - pathology</subject><subject>Cystadenocarcinoma, Serous - radiotherapy</subject><subject>Cystadenocarcinoma, Serous - surgery</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Low-grade serous carcinoma</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Obstetrics and Gynecology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - radiotherapy</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Serous ovarian tumor of low malignant potential</subject><subject>Survival Rate</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuu0zAQjRCIWy58ARLyil3C2HkvQEIVj0pXYsFjazn2pHVJ7GI7rbLjH_g1voAvwbntFRILWFn2ecx4ziTJUwoZBVq92GfzdjY2YwB1BjSDHO4lKwptmVZN2d5PVgAtpA0rm6vkkfd7gEih7GFyReucAS2rVfJzbceDcNpbQ2xPwg6JHLTRUgykw504ausWwOBpmInSYmusR0V8EFv0ZLP59f3H5gsZ7CndOqGQeHR28kQKJ7Wxo7hztUfhZnLSYRevIizPF-qCaGFImEbr_AJENzKKQW-NMIEcbEATdGzoVuhQTo4I_4-aj5MHvRg8Prmc18nnt28-rd-nNx_ebdavb1JZUBZSVTR9QXNVq7YVTS8qSivGRNvkiKprC9GXrBey6AqJrK971Uvoqk622DCa501-nTw_-x6c_TahD3zUXuIwCIOxIV5DmdMWqkjMz0TprPcOe35weowD4RT4Eibf89sw-RImB8pjUlH17GI_dSOqP5pLepHw8kzA-MmjRse91GgkKh2nFLiy-j8FXv2lv8v-K87o93ZyJs6PU-4ZB_5x2adlnaCOq1SWTf4bDQDNrA</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Shvartsman, Hyun S</creator><creator>Sun, Charlotte C</creator><creator>Bodurka, Diane C</creator><creator>Mahajan, Vrinda</creator><creator>Crispens, Marta</creator><creator>Lu, Karen H</creator><creator>Deavers, Michael T</creator><creator>Malpica, Anais</creator><creator>Silva, Elvio G</creator><creator>Gershenson, David M</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070601</creationdate><title>Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma</title><author>Shvartsman, Hyun S ; Sun, Charlotte C ; Bodurka, Diane C ; Mahajan, Vrinda ; Crispens, Marta ; Lu, Karen H ; Deavers, Michael T ; Malpica, Anais ; Silva, Elvio G ; Gershenson, David M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-d48f413d7d99a8fa611622a983eedb94af52fac4b4ce2f7fdfc0b6bc9e8213383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Cystadenocarcinoma, Serous - drug therapy</topic><topic>Cystadenocarcinoma, Serous - pathology</topic><topic>Cystadenocarcinoma, Serous - radiotherapy</topic><topic>Cystadenocarcinoma, Serous - surgery</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Low-grade serous carcinoma</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Obstetrics and Gynecology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - radiotherapy</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Serous ovarian tumor of low malignant potential</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shvartsman, Hyun S</creatorcontrib><creatorcontrib>Sun, Charlotte C</creatorcontrib><creatorcontrib>Bodurka, Diane C</creatorcontrib><creatorcontrib>Mahajan, Vrinda</creatorcontrib><creatorcontrib>Crispens, Marta</creatorcontrib><creatorcontrib>Lu, Karen H</creatorcontrib><creatorcontrib>Deavers, Michael T</creatorcontrib><creatorcontrib>Malpica, Anais</creatorcontrib><creatorcontrib>Silva, Elvio G</creatorcontrib><creatorcontrib>Gershenson, David M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shvartsman, Hyun S</au><au>Sun, Charlotte C</au><au>Bodurka, Diane C</au><au>Mahajan, Vrinda</au><au>Crispens, Marta</au><au>Lu, Karen H</au><au>Deavers, Michael T</au><au>Malpica, Anais</au><au>Silva, Elvio G</au><au>Gershenson, David M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>105</volume><issue>3</issue><spage>625</spage><epage>629</epage><pages>625-629</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Abstract Background. Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types. Methods. All patients with stages II–IV LGSC (group 1) or with STLMP that recurred as LGSC (group 2) seen at our institution from 1973 to 2003 were identified, and demographic data were obtained. For group 1, progression-free and overall survival times were calculated from the date of primary diagnosis to the date of disease progression/recurrence or the date of last contact/death, respectively. For group 2, progression-free and overall survival times were calculated from the date of first relapse as a LGSC to the date of progression or the date of last contact/death, respectively. The method of Kaplan and Meier was used to estimate survival, and the log-rank test was used to compare differences between survival curves. Results. We identified 112 patients in group 1 and 41 in group 2. There were no statistically significant differences between the two groups in median age (42.7 vs. 45.4 years [at relapse]; P = 0.37), progression-free survival time (19.5 vs. 25 months; P = 0.92), or overall survival time (81.8 vs. 82.8 months; P = 0.84). Conclusions. The age at diagnosis, progression-free survival time, and overall survival time associated with newly diagnosed stages II–IV LGSC of the ovary are similar to those of STLMP that recur as LGSC, providing further evidence of an association between these two tumor types.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>17320156</pmid><doi>10.1016/j.ygyno.2007.01.030</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 2007-06, Vol.105 (3), p.625-629
issn 0090-8258
1095-6859
language eng
recordid cdi_proquest_miscellaneous_70531906
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Adolescent
Adult
Aged
Cystadenocarcinoma, Serous - drug therapy
Cystadenocarcinoma, Serous - pathology
Cystadenocarcinoma, Serous - radiotherapy
Cystadenocarcinoma, Serous - surgery
Disease-Free Survival
Female
Hematology, Oncology and Palliative Medicine
Humans
Low-grade serous carcinoma
Middle Aged
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Obstetrics and Gynecology
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Ovarian Neoplasms - radiotherapy
Ovarian Neoplasms - surgery
Serous ovarian tumor of low malignant potential
Survival Rate
title Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T20%3A02%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20clinical%20behavior%20of%20newly%20diagnosed%20stages%20II%E2%80%93IV%20low-grade%20serous%20carcinoma%20of%20the%20ovary%20with%20that%20of%20serous%20ovarian%20tumors%20of%20low%20malignant%20potential%20that%20recur%20as%20low-grade%20serous%20carcinoma&rft.jtitle=Gynecologic%20oncology&rft.au=Shvartsman,%20Hyun%20S&rft.date=2007-06-01&rft.volume=105&rft.issue=3&rft.spage=625&rft.epage=629&rft.pages=625-629&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2007.01.030&rft_dat=%3Cproquest_cross%3E70531906%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70531906&rft_id=info:pmid/17320156&rft_els_id=1_s2_0_S0090825807000558&rfr_iscdi=true